Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioSante Pharmaceuticals nets $45.1mm through FOPO

Executive Summary

BioSante Pharmaceuticals Inc. (women’s health and cancer therapeutics) has netted $45.1mm through the follow-on public offering of 16mm common shares at $3. Some of the funds will be used to continue Phase III studies of LibiGel, a once-daily transdermal testosterone gel for hypoactive sexual desire disorder in women.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Transdermal
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies